Lethal Pulmonary Reactions Associated with the Combined Use of Amphotericin B and Leukocyte Transfusions
- 14 May 1981
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 304 (20), 1185-1189
- https://doi.org/10.1056/nejm198105143042001
Abstract
Amphotericin B is used increasingly in high-risk patients with profound neutropenia and suspected sepsis. We have observed serious pulmonary reactions characterized by acute dyspnea, hypoxemia, and interstitial infiltrates on chest films in patients receiving amphotericin B and leukocyte transfusions. We reviewed 6 1/2 years of experience at the National Institutes of Health to determine whether this combination was associated with pulmonary toxicity not characteristic of either therapy alone.This publication has 10 references indexed in Scilit:
- CONCOMITANT ADMINISTRATION OF GRANULOCYTE TRANSFUSIONS AND AMPHOTERICIN-B IN NEUTROPENIC PATIENTS - ABSENCE OF SIGNIFICANT PULMONARY TOXICITY1981
- Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicityBlood, 1981
- Therapeutic neutrophil transfusionsAmerican Journal Of Medicine, 1978
- SOME ASPECTS OF RECENT ADVANCES IN THE USE OF BLOOD CELL COMPONENTSBritish Journal of Haematology, 1978
- Consequences of Prior Alloimmunization during Granulocyte TransfusionTransfusion, 1977
- Principles of Granulocyte Transfusion TherapyMedical Clinics of North America, 1977
- Neutrophil Toxicity of Amphotericin BAntimicrobial Agents and Chemotherapy, 1977
- Successful Granulocyte Transfusion Therapy for Gram-Negative SepticemiaNew England Journal of Medicine, 1977
- Inhibition of human neutrophil chemotaxis and chemiluminescence by amphotericin BInfection and Immunity, 1976